<DOC>
<DOCNO>EP-0659743</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Piperidine derivatives as inhibitors of platelet aggregation and their preparation.
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D21100	C07D21132	C07D21142	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D211	C07D211	C07D211	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of formula I 

in which the substituents R₁-R₄, X,Y and n have the given meaning, show an 
activity as inhibitors of platelet aggregation. 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
HOECHST AG
</APPLICANT-NAME>
<APPLICANT-NAME>
HOECHST AKTIENGESELLSCHAFT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
The instant invention is directed to heterocyclic compounds, their preparation 
and their use, in particular their use as inhibitors of platelet aggregation. Known inhibitors of platelet aggregation have, for example, the following 
formulas: 
J. Amer. Chem. Soc., 1992, 114, 9699-9701. 
US Patent 5,039,805, 1991.  EP 0 483 667 
EP 0 445 796 
J. Med. Chem., 36 (21), 3039-3049, 1993.  EP 0 483 667
 
Surprisingly, it has now been found, that the heterocyclic compounds according 
to the instant invention have an activity as inhibitors of platelet aggregation. Accordingly, the subject of the instant invention are compounds of formula I 
wherein, 
R₁ =H, C₁-C₁₀-alkyl, C(=NH)-NH₂, C(=NH)-NHR₅ wherein R₅ is C₁-C₄-alkyl, 
C(=O)-C₁-C₄-alkyl, C(=O)-C₁-C₄-alkyl-aryl, C(=O)-aryl, C(=O)-substituted 
aryl, S(=O)₂-C₁-C₄-alkyl, S(=O)-aryl, S(=O)₂-aryl, S(=O)₂-substituted 
aryl;
 
C(=O)-C₁-C₁₀-alkyl-NH₂, C(=O)-C₁-C₁₀-alkyl-NH-C₁-C₄-alkyl, C(=O)-C₁-C₁₀-alkyl-N(C₁-C₄-alkyl)₂, 
C(=O)-C₁-C₁₀-alkyl-NH-C(=O)-NH₂, C(=O)-C₁-C₁₀-alkyl-NH-C(=O)-NH-C₁-C₄-alkyl, 
C(=O)-C₁-C₁₀-alkyl-NH-(=NH)-NH₂, 
C₁-C₄-alkyl-C(=NH)-NH₂, C(O)-C₁-C₄-alkyl-C(=NH)-NH₂, C(=O)-C₁-C₁₀-alkyl-NH-C(=NH)-NH-R₅, 
wherein R₅ is as defined above;  R₂ =H, one, two or three substituents, which are the same of different, 
selected from the group consisting of C₁-C₄-alkyl, OH, O-C₁-C₄-alkyl, O-C(=O)-C₁-C₄-alkyl, 
O-C(=O)-C₁-C₄-alkyl-aryl, O-C(=O)-NH₂, O-C(=O)-NH-C₁-C₄alkyl, 
O-C(=O)-NH-aryl, O-C(=O)-N(C₁-C₄-alkyl)₂; R₃ =H, one, two or three substituents, which are the same of different, 
selected from the group consisting of C₁-C₄-alkyl, 
O-C₁-C₄-alkyl, F, Cl, Br, OH, O-C(=O)-C₁-C₄-alkyl, NH₂NH-C₁-C₄-alkyl, 
N(C₁-C₄-alkyl)₂, NH-C(=O)-C₁-C₄-alkyl, NH-C(=O)-aryl, NH-C(=O)-NH₂, 
COOH, C(=O)-O-C₁-C₄-alkyl, C(=O)-NH₂, C(=O)-NH-C₁-C₄-alkyl, 
C(=O)-N(C₁-C₄-alkyl)₂, C₁-C₄-COOH, C₁-C₄-alkyl-C(=O)-O-C₁-C₄-alkyl; X =O, S, C(=O), C(=S), CH-C₁-C₄-alkyl, C(C₁-C₄-alkyl)₂, CHOH, ((OH)-C₁-C₄-alkyl; Y =C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₄-alkyl-aryl, C₂-C₆-alkenyl-aryl, 
C₂-C₆-alkynyl-aryl, C₁-C₄-alkyl-substituted aryl, C₁-C₄-alkenyl-substituted-aryl, 
C₁-C₄-alkyl-heteroaryl, C₁-C₄-alkenyl-heteroaryl, 
aryl, substituted aryl, heteroaryl and substituted heteroaryl; R₄ =H, one, two or three substituents, which are the same of different, 
selected from the group consisting of SO₃H, C(=O)-R₆, C₁-C₁₀-alkyl-C(=O)-R₆, 
C₂-C₁₀-alkenyl-C(=O)-R₆, C₂-C₁₀-alkynyl-C(=O)-R₆, O-C₁-C₁₀-alkyl-C(=O)-R₆, 
H-N-C(=O)-C₁-C₁₀-alkyl-C(=O)-R₆, N(C₁-C₄-alkyl)-C(=O)-C₁-C₁₀-alkyl-C(=O)-R₆, 
C(=O)-N
</DESCRIPTION>
<CLAIMS>
Compounds of formula I 
 

wherein, 
R₁ =H, C₁-C₁₀-alkyl, C(=NH)-NH₂, C(=NH)-NHR₅ wherein R₅ is C₁-C₄-alkyl, 

C(=O)-C₁-C₄-alkyl, C(=O)-C₁-C₄-alkyl-aryl, C(=O)-aryl, C(=O)-substituted 
aryl, S(=O)₂-C₁-C₄-alkyl, S(=O)-aryl, S(=O)₂-aryl, S(=O)₂-substituted 

aryl; 
C(=O)-C₁-C₁₀-alkyl-NH₂, C(=O)-C₁-C₁₀-alkyl-NH-C₁-C₄-alkyl, C(=O)-C₁-C₁₀-alkyl-N(C₁-C₄-alkyl)₂, 

C(=O)-C₁-C₁₀-alkyl-NH-C(=O)-NH₂, C(=O)-C₁-C₁₀-alkyl-NH-C(=O)-NH-C₁-C₄-alkyl, 
C(=O)-C₁-C₁₀-alkyl-NH-(=NH)-NH₂, 

C₁-C₄-alkyl-C(=NH)-NH₂, C(=O)-C₁-C₄-alkyl-C(=NH)-NH₂, C(=O)-C₁-C₁₀-alkyl-NH-C(=NH)-NH-R₅, 
wherein R₅ is as defined above; R₂ =H, one, two or three substituents, which are the same of different, 

selected from the group consisting of C₁-C₄-alkyl, OH, O-C₁-C₄-alkyl, O-C(=O)-C₁-C₄-alkyl, 
O-C(=O)-C₁-C₄-alkyl-aryl, O-C(=O)-NH₂, O-C(=O)-NH-C₁-C₄-alkyl, 

O-C(=O)-NH-aryl, O-C(=O)-N(C₁-C₄-alkyl)₂; R₃ =H, one, two or three substituents, which are the same of different, 
selected from the group consisting of C₁-C₄-alkyl, 

O-C₁-C₄-alkyl, F, Cl, Br, OH, O-C(=O)-C₁-C₄-alkyl, NH₂NH-C₁-C₄-alkyl, 
 

NH-C(=O)-C₁-C₄-alkyl, NH-C(=O)-aryl, N(C₁-C₄-alkyl)₂, NH-C(=O)-NH₂, 
COOH, C(=O)-O-C₁-C₄-alkyl, C(=O)-NH₂, C(=O)-NH-C₁-C₄-alkyl, 

C(=O)-N(C₁-C₄-alkyl)₂, C₁-C₄-COOH, C₁-C₄-alkyl-C(=O)-O-C₁-C₄-alkyl; X =O, S, C(=O), C(=S), CH-C₁-C₄-alkyl, C(C₁-C₄-alkyl)₂, CHOH, C(OH)-C₁-C₄-alkyl; Y =C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₄-alkyl-aryl, C₂-C₆-alkenyl-aryl, 
C₂-C₆-alkynyl-aryl, C₁-C₄-alkyl-substituted aryl, C₁-C₄-alkenyl-substituted-aryl, 

C₁-C₄-alkyl-heteroaryl, C₁-C₄-alkenyl-heteroaryl, 
aryl, substituted aryl, heteroaryl and substituted heteroaryl; R₄ =H, one, two or three substituents, which are the same of different, 

selected from the group consisting of SO₃H, C(=O)-R₆, C₁-C₁₀-alkyl-C(=O)-R₆, 
C₂-C₁₀-alkenyl-C(=O)-R₆, C₂-C₁₀-alkynyl-C(=O)-R₆, O-C₁-C₁₀-alkyl-C(=O)-R₆, 

H-N-C(=O)-C₁-C₁₀-alkyl-C(=O)-R₆, N(C₁-C₄-alkyl)-C(=O)-C₁-C₁₀-alkyl-C(=O)-R₆, 

C(=O)-NH-C₁-C₁₀-alkyl-C(=O)-R₆; 
wherein R₆ is OH, C₁-C₄-alkyl, C₁-C₄-alkyl-aryl, aryl, substituted aryl, 

NH₂, NH-C₁-C₄-alkyl, N(C₁-C₄-alkyl)₂; n =0, 1 or 2,  
as well as the physiologically tolerable addition salts thereof. 
Compounds of formula II as claimed in claim 1, 

 

wherein 
R₁ =H, C₁-C₄-alkyl, C(=NH)-NH₂, C(=NH)-NHR₅ wherein R₅ is as defined in 

claim 1 C₁-C₄-alkyl-C(=NH)-NH₂, C(=O)-C₁-C₄-alkyl-C(=NH)-NH₂; R₂ =H, one or two substituents, which are the same of different, selected 
from the group consisting of C₁-C₄-alkyl, O-C₁-C₄-alkyl, OH, 

O-C(=O)-C₁-C₄-alkyl, O-C(=O)-C₁-C₄-alkyl-aryl, O-C(=O)-NH-C₁-C₄-alkyl, 
O-C(=O)-NH-aryl; R₃ =H, one or two substituents, which are the same of different, selected 

from the group consisting of OH, O-C₁-C₄-alkyl, O-C(=O)-C₁-C₄-alkyl, F, 
Cl, Br, NH₂, NH-C₁-C₄-alkyl, N(C₁-C₄-alkyl)₂, NH-C(=O)-C₁-C₄-alkyl, NH-C(=O)-aryl, 

COOH, C(=O)-O-C₁-C₄-alkyl; X =C = O, CHOH, C(OH)-C₁-C₄-alkyl, C(C₁-C₄-alkyl)₂, CH(C₁-C₄-alkyl); Y =C₁-C₄-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₁-C₄-alkyl-aryl, C₂-C₄-alkenyl-aryl, 
C₂-C₄-alkynyl-aryl, C₁-C₄-alkyl-substituted aryl, C₁-C₄-alkenyl-substituted-aryl, 

C₁-C₄-alkyl-heteroaryl, C₁-C₄-alkenyl-heteroaryl, aryl, 
substituted aryl, heteroaryl and substituted heteroaryl; R₄ =H, one or two substituents, which are the same of different, selected 

from the group consisting of SO₃H and groups represented by C(=O)-R₆, 
C₁-C₄-alkyl-C(=O)-R₆, C₂-C₄-alkenyl-C(=O)-R₆, C₂-C₄-alkynyl-C(=O)-R₆, 

O-C₁-C₄-alkyl-C(=O)-R₆, NH-C(=O)-C₁-C₄-alkyl-C(=O)-R₆, N(C₁-C₄-alkyl)-C(=O)-C₁-C₄-alkyl-C(=O)-R₆, 
C(=O)-NH-C₁-C₄-alkyl-C(=O)-R₆, 

wherein, R₆ is as defined in claim 1. 
Compounds of formula III, as claimed in claims 1 or 2 
 

wherein, 
R₁ =H, C₁-C₄-alkyl, C(=NH)-NH₂, C(=NH)-NHR₅ wherein R₅ is as defined in 

claim 1 C₁-C₄-alkyl-C(=NH)-NH₂, C(=O)-C₁-C₄-alkyl-C(=NH)-NH₂. R₂ =H, C₁-C₄-alkyl, O-C₁-C₄-alkyl, OH, O-C(=O)-C₁-C₄-alkyl, O-C(=O)-C₁-C₄-alkyl-aryl, 
O-C(=O)-NH-C₁-C₄-alkyl, O-C(=O)-NH-aryl; R₃ =H, or a substituent selected from the group consisting of OH, O-C₁-C₄-alkyl, 

O-C(=O)-₁-C₄-alkyl, F, Cl, Br, NH₂, NH-C₁-C₄-alkyl, N(C₁-C₄-alkyl)₂, 
NH-C(=O)-C₁-C₄-alkyl, NH-C(=O)-aryl, COOH, C(=O)-O-C₁-C₄-alkyl; Y =C₁-C₄-alkyl, C₂-C₄-alkenyl and C₂-C₄-alkynyl: R₄ =H, or a substituent selected from the group consisting of SO₃H, and 

groups represented by C(=O)-R₆, C₁-C₄-alkyl-C(=O)-R₆, C₂-C₄-alkenyl-C(=O)-R₆, 
C₂-C₄-alkynyl-C(=O)-R₆, O-C₁-C₄-alkyl-C(=O)-R₆, NH-C(=O)-C₁-C₄-alkyl-C(=O)-R₆, 

N(C₁-C₄-alkyl)-C(=O)-C₁-C₄-alkyl-C(=O)-R₆, 
C(=O)-NH-C₁-C₁₀-alkyl-C(=O)-R₆, wherein, R₆ is OH, C₁-C₄-alkyl, C₁-C₄-alkyl-aryl, 

aryl, substituted aryl, NH₂, NH(C₁-C₄-alkyl), N(C₁-C₄-alkly)₂. 
A process for the production of a compound as claimed in one or more of 
claims 1-3, wherein a compound formula V 

 
is reacted with a compound of formula VI to give a compound of formula 

VII 
 

which in turn is optionally catalytically hydrogenated to a compound of 
formula VIII 

 
wherein the substituents R₁ - R₄ have the denotations. 
The compounds as claimed in one or more of claims 1-3 as a 
pharmaceutical 
The use of the compounds as claimed in one or more of claims 1-3 for 
the production of a pharmaceutic with an activity against platelet 

aggregation. 
A pharmaceutical having an active amount of one or more compounds as 
claimed in one or more of claims 1-3 optionally together with 

physiologically tolerable carriers and/or excipients. 
A process for the production of a pharmaceutical as claimed in claim 7, 
wherein at least one compound as claimed in claims 1-3 is brought, 

optionally together with physiologically tolerable carriers and/or excipients 
into a suitable form for administration. 
</CLAIMS>
</TEXT>
</DOC>
